StockNews.AI
PFE
StockNews.AI
125 days

ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

1. CDC expanded recommendation for RSV vaccines for at-risk adults aged 50-59. 2. This includes Pfizer's ABRYSVO® vaccine, boosting potential market share.

2m saved
Insight
Article

FAQ

Why Bullish?

The CDC recommendation can enhance ABRYSVO® sales, similar to COVID-19 vaccine impacts.

How important is it?

The recommendation is vital in strengthening Pfizer's position during RSV season and potentially increasing sales.

Why Long Term?

Increased vaccine adoption can lead to sustained revenue growth over several years.

Related Companies

MRNAJNJABT
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug.

Related News